TransThera Sciences Nanjing Inc (2617 HK) is a Chinese company specializing in the biotechnology industry. TransThera Sciences plans to list on the Hong Kong Stock Exchange on June 23, 2025, offering 15.28 million shares at HKD 13.15 apiece, raising HKD 200.95 million (USD 25.60 million). The company's market capitalization at the time of the offer is USD 664.93 million. The IPO proceeds will reportedly be used to advance critical Phase III trials for its drug, Tinengotinib, as well as for broader corporate projects. According to sources, key investors, including Jiangbei Pharmaceutical and Akeso, have pre-committed to purchasing over 64% of the shares offered.